ea0041nsa2 | (1) | ECE2016
Laronda Monica M
Patients with gonadotoxicity due to disease treatment, or who face primary gonadal insufficiency as a result of genetic causes, have limited options for long-term endocrine and fertility support. Current fertility options, such as egg or embryo banking, exclude women with hormone-responsive cancers and pre-pubertal children. This highlights the urgency of addressing this currently unmet need with innovative engineering solutions. Our objective is to create an ovary bioprosthes...